“WE CONTRIBUTE TO SOCIAL PROGRESS BY LEADING RESEARCH THAT BRINGS US CLOSER TO DISCOVERING NEW TREATMENTS”
Víctor Grífols Roura
“THIS REPORT REFLECTS THE EFFORTS OF EVERYONE WHO FORMS PART OF THE GRIFOLS TEAM, AS WELL AS OUR “ONE GRIFOLS” MODEL OF RESPONSIBLE MANAGEMENT”
A robust and reliable corporate governance structure is vital to generating long-term sustainability and value. Integrity, leadership, transparency and compliance with the highest ethical standards are the essence of Grifols’ corporate governance.
Honesty, ethics, transparency, integrity and compliance form the foundation of our corporate values. We believe that doing things well creates value.
Grifols is fully committed to compliance with all applicable laws and rules. Its corporate policies include a Code of Ethics, Code of Conduct, Anti-Corruption Policy and Crime-Prevention Policy, among others.
In 2018, Grifols had no confirmed incidents of corruption in the markets where it operates.
As manufacturers of products which are vital to people's health and well-being, Grifols ensures the highest levels of safety and quality in everything we do.
Grifols advocates safety and quality in every stage of the value chain. Its vertically integrated business model further enhances its control over production processes.
In 2018, the company underwent more than 700 compliance inspections and internal audits, and conducted over 270 supplier quality audits, testament to its staunch commitment to quality and safety.
A leader in the global healthcare sector, Grifols generates value, employment, innovation and capital investments.
We aspire to make a positive impact on society. We actively collaborate with local communities, research organizations and academic institutions.
We are committed to ensuring our operations are efficient and respectful of the environment. Long-term growth is impossible without sustainability.
Grifols’ 2017-2019 Environmental Program establishes targets to reduce water consumption in the existing facilities, increase waste recycling, and incorporate new eco-friendly installations in the company’s manufacturing network, among others.
In 2018, the program achieved its main objectives and allocated €18 million toward environmental initiatives.
Grifols strives to promote the personal and professional development of its global talent pool, which it considers among its most critical assets.
Equal opportunities, non-discrimination, diversity and integration underpin Grifols’ human resource approach:
We dedicate significant resources – both human and economic – to innovation. While success is never guaranteed, Grifols is fully committed to contributing to social and scientific progress.
Grifols’ R&D+i strategy combines in-house initiatives with external investments and collaborations. The company allocated €291 million in R&D+i in 2018 and currently holds 2,965 global patents and patent applications, a reflection of its pioneering spirit.
The topline results of the AMBAR clinical trial for the treatment of Alzheimer’s are very encouraging for patients in the mild and moderate stages of the disease. This outcome inspires Grifols’ to continue its research in the fight against this debilitating disease.